Pharmacokinetics of the aldose reductase inhibitor tolrestat: Studies in healthy young and elderly male and female subjects and in subjects with diabetes

Richard Fruncillo, Steven Troy, Vernon Parker, Michael Mayersohn, David Hicks, Michael Kraml, Michele Battle, Soong Chiang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tolrestat is an aldose reductase inhibitor undergoing clinical trials in diabetic subjects that may reduce the severity of chronic tissue damage associated with hyperglycemia. These studies were conducted to evaluate the pharmacokinetics of tolrestat in healthy young and elderly male and female subjects and in young and elderly subjects with diabetes. The drug was administered in a multiple-dose regimen, and steady-state parameters were obtained. There were no important gender-related differences, but mean values for apparent oral clearance, renal clearance, and corresponding unbound parameters were significantly lower for the elderly healthy subjects than for the young healthy subjects. The drug is highly bound to plasma proteins, and the unbound fraction (0.75%) did not differ among the subjects. The results from young and elderly diabetic subjects suggest. that diabetes per se has no influence on tolrestat disposition but that there is an age-related reduction in apparent oral clearance (30 versus 18 ml/hr/kg) and a corresponding increase in the minimum steady-state plasma concentration (1.2 versus 1.9 μg/ml). These data indicate a possible need to reduce the dose of tolrestat in elderly subjects, assuming the same concentration-response relationship.

Original languageEnglish (US)
Pages (from-to)603-612
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume59
Issue number6
DOIs
StatePublished - Jun 1996
Externally publishedYes

Fingerprint

Aldehyde Reductase
Pharmacokinetics
Healthy Volunteers
Hyperglycemia
Pharmaceutical Preparations
tolrestat
Clinical Trials
Kidney

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacokinetics of the aldose reductase inhibitor tolrestat : Studies in healthy young and elderly male and female subjects and in subjects with diabetes. / Fruncillo, Richard; Troy, Steven; Parker, Vernon; Mayersohn, Michael; Hicks, David; Kraml, Michael; Battle, Michele; Chiang, Soong.

In: Clinical Pharmacology and Therapeutics, Vol. 59, No. 6, 06.1996, p. 603-612.

Research output: Contribution to journalArticle

Fruncillo, Richard ; Troy, Steven ; Parker, Vernon ; Mayersohn, Michael ; Hicks, David ; Kraml, Michael ; Battle, Michele ; Chiang, Soong. / Pharmacokinetics of the aldose reductase inhibitor tolrestat : Studies in healthy young and elderly male and female subjects and in subjects with diabetes. In: Clinical Pharmacology and Therapeutics. 1996 ; Vol. 59, No. 6. pp. 603-612.
@article{7e48d6783c834bc3a1da39713edee6e7,
title = "Pharmacokinetics of the aldose reductase inhibitor tolrestat: Studies in healthy young and elderly male and female subjects and in subjects with diabetes",
abstract = "Tolrestat is an aldose reductase inhibitor undergoing clinical trials in diabetic subjects that may reduce the severity of chronic tissue damage associated with hyperglycemia. These studies were conducted to evaluate the pharmacokinetics of tolrestat in healthy young and elderly male and female subjects and in young and elderly subjects with diabetes. The drug was administered in a multiple-dose regimen, and steady-state parameters were obtained. There were no important gender-related differences, but mean values for apparent oral clearance, renal clearance, and corresponding unbound parameters were significantly lower for the elderly healthy subjects than for the young healthy subjects. The drug is highly bound to plasma proteins, and the unbound fraction (0.75{\%}) did not differ among the subjects. The results from young and elderly diabetic subjects suggest. that diabetes per se has no influence on tolrestat disposition but that there is an age-related reduction in apparent oral clearance (30 versus 18 ml/hr/kg) and a corresponding increase in the minimum steady-state plasma concentration (1.2 versus 1.9 μg/ml). These data indicate a possible need to reduce the dose of tolrestat in elderly subjects, assuming the same concentration-response relationship.",
author = "Richard Fruncillo and Steven Troy and Vernon Parker and Michael Mayersohn and David Hicks and Michael Kraml and Michele Battle and Soong Chiang",
year = "1996",
month = "6",
doi = "10.1016/S0009-9236(96)90000-4",
language = "English (US)",
volume = "59",
pages = "603--612",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics of the aldose reductase inhibitor tolrestat

T2 - Studies in healthy young and elderly male and female subjects and in subjects with diabetes

AU - Fruncillo, Richard

AU - Troy, Steven

AU - Parker, Vernon

AU - Mayersohn, Michael

AU - Hicks, David

AU - Kraml, Michael

AU - Battle, Michele

AU - Chiang, Soong

PY - 1996/6

Y1 - 1996/6

N2 - Tolrestat is an aldose reductase inhibitor undergoing clinical trials in diabetic subjects that may reduce the severity of chronic tissue damage associated with hyperglycemia. These studies were conducted to evaluate the pharmacokinetics of tolrestat in healthy young and elderly male and female subjects and in young and elderly subjects with diabetes. The drug was administered in a multiple-dose regimen, and steady-state parameters were obtained. There were no important gender-related differences, but mean values for apparent oral clearance, renal clearance, and corresponding unbound parameters were significantly lower for the elderly healthy subjects than for the young healthy subjects. The drug is highly bound to plasma proteins, and the unbound fraction (0.75%) did not differ among the subjects. The results from young and elderly diabetic subjects suggest. that diabetes per se has no influence on tolrestat disposition but that there is an age-related reduction in apparent oral clearance (30 versus 18 ml/hr/kg) and a corresponding increase in the minimum steady-state plasma concentration (1.2 versus 1.9 μg/ml). These data indicate a possible need to reduce the dose of tolrestat in elderly subjects, assuming the same concentration-response relationship.

AB - Tolrestat is an aldose reductase inhibitor undergoing clinical trials in diabetic subjects that may reduce the severity of chronic tissue damage associated with hyperglycemia. These studies were conducted to evaluate the pharmacokinetics of tolrestat in healthy young and elderly male and female subjects and in young and elderly subjects with diabetes. The drug was administered in a multiple-dose regimen, and steady-state parameters were obtained. There were no important gender-related differences, but mean values for apparent oral clearance, renal clearance, and corresponding unbound parameters were significantly lower for the elderly healthy subjects than for the young healthy subjects. The drug is highly bound to plasma proteins, and the unbound fraction (0.75%) did not differ among the subjects. The results from young and elderly diabetic subjects suggest. that diabetes per se has no influence on tolrestat disposition but that there is an age-related reduction in apparent oral clearance (30 versus 18 ml/hr/kg) and a corresponding increase in the minimum steady-state plasma concentration (1.2 versus 1.9 μg/ml). These data indicate a possible need to reduce the dose of tolrestat in elderly subjects, assuming the same concentration-response relationship.

UR - http://www.scopus.com/inward/record.url?scp=0030017101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030017101&partnerID=8YFLogxK

U2 - 10.1016/S0009-9236(96)90000-4

DO - 10.1016/S0009-9236(96)90000-4

M3 - Article

C2 - 8681485

AN - SCOPUS:0030017101

VL - 59

SP - 603

EP - 612

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -